 SAN DIEGO, March 10, 2021 PRNewswire -- MEI Pharma, Inc. NASDAQ: MEIP, a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the abstract, Voruciclib, a CDK9 inhibitor, downregulates MYC and inhibits proliferation of KRAS mutant cancers in preclinical models, was selected for an E-Poster Session presentation at the American Association for Cancer Research AACR Annual Meeting 2021 and will be available on April 10, 2021. Voruciclib is an orally available inhibitor of cyclin-dependent kinase 9 CDK9, part of a family of regulatory enzymes important to cell cycle regulation associated with cell proliferation and increased survival. 